drugset
drugset / Trial / NCT02569125

Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

NCT02569125 ↗

Phase 2 Withdrawn Jochen Roessler Clinical Trials Unit Freiburg · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, single-arm, phase II clinical trial of Everolimus (RAD001) in patients with segmental overgrowth syndrome.

Timeline

Start
2016-01
Primary completion
2016-01
Completion
2016-02

Outcome

Outcome not reported

Stopped: “Change in supply of study medication”

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 4.5 mg/m2 —

Indications

overgrowth syndrome